{
    "success": true,
    "data": {
        "leverage": false,
        "derivatives": false,
        "swaps": false,
        "inverse": false,
        "replication_method": "physical",
        "ucits": true,
        "type": "ETF",
        "complex_factors": [
            "Complex Underlying Technology/Index Risks",
            "Unregulated and Speculative Nature of Underlying Blockchain Technology"
        ],
        "classification": "complex",
        "supporting_data": "The ETF is a UCITS fund, generally presumed non-complex. It uses physical replication to track the Indxx Blockchain Index, which typically supports a non-complex classification. The KIID indicates that derivatives are not central to its investment objective, but rather that the fund invests 'primarily in equity securities that are included in the Index' and may use 'depository receipts to gain exposure' where direct investment is not possible, which aligns with physical replication rather than synthetic replication or integral derivative use. No leverage, swaps, or inverse strategies are mentioned. However, the comprehensive description of the 'blockchain technology risk' within the KIID indicates that the underlying index and the companies it tracks are exposed to significant, non-standard risks. The KIID explicitly states risks such as 'entirely new and relatively untested technology', 'vulnerable to fraud', 'little regulation', 'speculative, unregulated and volatile digital currency', and 'less liquidity for such assets and greater possibility of fraud or manipulation'. These risks, inherent to the underlying technology and its market, are beyond the typical market volatility and require knowledge that is likely difficult for a retail investor with basic financial literacy to fully understand. Therefore, while the ETF's structure is physically replicated, the inherent nature and risks of the underlying index's subject matter make the product's risks opaque and difficult to comprehend for an average retail investor, overturning the general UCITS presumption of non-complexity, as per MiFID II Article 254, Delegated Regulation EU 2017/565 Article 57, and ESMA guidelines emphasizing the ease of understanding the product's risks."
    }
}